Informações:
Falhas:
ID
34287
Descrição
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01486966
Link
https://clinicaltrials.gov/show/NCT01486966
Palavras-chave
Versões (1)
- 16/01/2019 16/01/2019 -
Titular dos direitos
see on clinicaltrials.gov
Transferido a
16 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Diabetes NCT01486966
Eligibility Diabetes NCT01486966
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT01486966
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
type 2 diabetes mellitus (diagnosed clinically) for at 12 months or longer
boolean
ID.2
Item
currently treated with basal insulin once daily or premixed insulin twice daily for at least 3 months with or without oad(s), and total daily insulin dose less than 1.4 iu (u)/kg (if treated with metformin, unchanged total daily dose of at least 1000 mg for at least 3 months)
boolean
ID.3
Item
body mass index (bmi) equal to 40 kg/m^2 or below
boolean
ID.4
Item
hba1c (glycosylated haemoglobin a1c) between 7.0% and 10.0% by central laboratory analysis
boolean
ID.5
Item
plan to be admitted for optimising glycaemic control at least 2 days prior to the randomisation
boolean
ID.6
Item
treatment with thiazolidinediones (tzd) or glucagon-like peptide-1 (glp-1) receptor agonists within the last 3 months prior to the screening
boolean
ID.7
Item
anticipated change after the randomisation in concomitant medication known to interfere with glucose metabolism, such as systemic corticosteroids, beta-blockers and mono amine oxidase (mao) inhibitors
boolean
ID.8
Item
previous participation in this trial (participation is defined as randomised. re-screening of screening failures is allowed only once within the limits of the recruitment period.)
boolean